Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Material AgreementItem 1.01 · 8-KLOW RiskPositive

Maravai LifeSciences Holdings, Inc.

www.maravai.com
Filed: Jun 2, 2026San Diego, CaliforniaCIK: 0001823239Health Care
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Maravai LifeSciences secured a new $150 million term loan and $30 million revolving credit facility maturing in 2032, using proceeds to refinance and prepay prior debt obligations, enhancing liquidity and reducing overall debt burden.

Key Takeaways

New credit agreement provides $150M term loan and $30M revolving facility, both maturing June 2, 2032

Company used new term loan proceeds plus $98.5M in cash to fully prepay and terminate prior Credit Agreement

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJun 2, 2026
Item1.01
CategoryMaterial Agreement
CIK0001823239
Accession #mrvi-20260602
Risk LevelLOW
SentimentPositive
Signalopportunity
Topics
debt financing

What This Means

The company entered into a significant agreement that could materially affect its business. This often signals new partnerships, licensing deals, or major contracts.
View Full Filing on SEC.govBrowse More Filings